About COVID-19Coronavirus disease is a highly infectious and contagious disease outbreaking all over the world. It is commonly called as COVID-19. Currently, more than 160 countries are battling with this deadly disease. The first case of coronavirus disease (COVID-19) was first reported in Wuhan, China on 31 December 2019. The disease is caused by a new virus namely Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or Novel coronavirus. The virus had not been previously identified in humans and similar to the SARS virus (SARS-CoV-1).
Reason for RFP on COVID-19COVID-19 has been declared as a pandemic by WHO due to the alarming levels of spread and severity. What makes it worst is as of now there is no specific medicine or vaccine to treat or prevent this disease. Project proposals are being requested for developing Diagnostics, Vaccines, Novel Therapeutics, Repurposing of Drugs or any other intervention for control of COVID-19 by companies, industries, LLP, Academia etc to support the preparedness, readiness and response for COVID-19.
Theme of the RFPThe theme of the RFP is: "Developing Diagnostics, Vaccines, novel Therapeutics, repurposing of drugs and any other intervention for control of COVID-19 outbreak".
Scope of the RFPThe scope of the RFP is inclusive of and not exhaustive of the following areas:
Development of technologies for the diagnosis of coronavirus (SARS-CoV-2) including various diagnostic methods like ELISA, Molecular diagnostics (PCR and Real-Time PCR), Lateral Flow assay, cell culture, Chemiluminescence, Colorimetric tests, Immunoassays etc.
Studies of vaccine technology platforms, novel vaccine manufacturing technologies, vaccine candidates including DNA, RNA, Live Attenuated Virus, Non-Replicating Viral Vector, Protein Subunit, Replicating Viral Vector at any stage of development and enabling disciplines for coronavirus vaccine development. To study in-licensing technology for optimization, scale-up and manufacturing
Development of in-vitro assay/animal models, new methods of B-cell isolation, monoclonal antibody development and standardize challenge studies. Besides, screening of existing libraries (Biologicals and Chemicals) and identify potential hits for development.
Repurposing of Drugs
Development of precautionary measures and treatment action studies and evaluation of the effect of existing marketed drugs in patients of COVID-19 under a standard protocol.
Any other technology related to outbreak prevention and control of SARS-CoV-2.
Main Requirements for the Proposal Consideration
Areas of Exclusion
DurationProject duration will be maximum up to 24 months. However, it is encouraged to develop the solution earlier if possible in 6-12 months.
Funding SupportFunding assistance will be provided based on the activities proposed in the proposal, available under DBT/different schemes of BIRAC/Ind-CEPI/National Biopharma Mission.
Eligibility for Proposals Submission
Note: The applicant Company/LLP should have sufficient in-house facility for the proper project implementation.
The application can be submitted by any of the above entities (a – d) jointly or individually.
Selection ProcessThe evaluation process will include the following steps:
Evaluation CriteriaSelection of proposal will be based on the following criteria:
Project MonitoringAn expert committee will be formed by BIRAC to monitor each project. Site visits shall also be done by 2-3 technical experts and one financial expert of Expert Committees comprising. The Project Monitoring Committee (PMC) will monitor the project progress, the outputs, milestones, targets and objectives as per the Agreement. BIRAC will release next instalment of grant only after the review of the project progress.
Reporting of Progress
Terms and Conditions
All successful applicants need to sign the Grant-in-aid Letter Agreement (GLA) with BIRAC.
In addition to the signing of an agreement between all the concerned parties, the following requirement needs to be completed before the first instalment can be released:
Contact InformationIn case of any query regarding RFP, candidates can contact
Further information can be obtained on the website of BIRAC.